PDE5A and erectile dysfunction: The current literature indicates significant patient and partner preferences for PDE5 inhibitors for erectile dysfunction (ED), with tadalafil as the agent of choice on account of the long duration of action, flexible dosing interval, and simplicity of use—most significantly among younger men and female partners.